Brand name: Libtayo TM
Active ingredients: cemiplimab
What it is used for
Cutaneous Squamous Cell Carcinoma,LIBTAYO as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.,Non-Small Cell Lung Cancer,LIBTAYO as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 tumour proportion score (TPS) greater than and equal to 50% as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have:, locally advanced NSCLC and who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.,LIBTAYO in combination with platinum-based chemotherapy is indicated for the first-line treatment of patients with NSCLC whose tumours have no EGFR, ALK or ROS1 aberrations and is:, locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or, metastatic.,Basal Cell Carcinoma,LIBTAYO as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.
How to take it
The way to take this medicine is: Intravenous Infusion.
- Store at 2 to 8 degrees Celsius
- Refrigerate
- Do not Freeze
- Protect from Light
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution. May contain trace amounts of translucent to white particles in a single-use vial
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient cemiplimab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
